Acadia Pharmaceuticals is purchasing a small Texas startup, CerSci, for $52 million in order to acquire a pain drug in the early stages of development, the company said Tuesday.
If the drug succeeds, CerSci could receive an additional $887 million in payments for hitting commercial and development milestones.
The deal is part of the company’s effort to expand on the financial success of Nuplazid, its drug for Parkinson’s-related psychosis, which generated $339 million in 2019 sales, chief executive Stephen Davis said in an interview with STAT.
About the Author Reprints
